SCHEMBL2145696

SCHEMBL2145696

CCCCCCC(O)CCCCCCCCCC=CO

nearest known ligand 0.53

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 2/20 0.53
FFAR4 Q5NUL3 2/20 0.53
GPR84 Q9NQS5 5/20 0.46
MEN1 O00255 1/20 0.46
CYP3A4 P08684 1/20 0.46
KMT2A Q03164 1/20 0.46
FAAH O00519 3/20 0.46
PPARG P37231 2/20 0.44
GPR132 Q9UNW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15547360 1.00 FFAR1 (0.53) FFAR1FFAR4GPR84MEN1CYP3A4
SCHEMBL28585490 1.00 FFAR1 (0.53) FFAR1FFAR4GPR84MEN1CYP3A4
SCHEMBL6015976 1.00 FFAR1 (0.53) FFAR1FFAR4GPR84MEN1CYP3A4
SCHEMBL31197028 0.98 FFAR1 (0.51) FFAR1FFAR4GPR84MEN1CYP3A4
SCHEMBL21552054 0.92 FFAR1 (0.45) FFAR1FFAR4GPR84MEN1CYP3A4
SCHEMBL21552055 0.92 FFAR1 (0.45) FFAR1FFAR4GPR84MEN1CYP3A4
SCHEMBL10081525 0.90 FFAR1 (0.62) FFAR1FFAR4GPR84MEN1CYP3A4
SCHEMBL2826342 0.90 FFAR1 (0.62) FFAR1FFAR4GPR84MEN1CYP3A4
SCHEMBL3185051 0.90 FFAR1 (0.62) FFAR1FFAR4GPR84MEN1CYP3A4
SCHEMBL17744144 0.90 FFAR1 (0.62) FFAR1FFAR4GPR84MEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8471007-B2 Method for producing 1,3,5-triazine carbamates and ureas BASF SE (DE) 2013-06-25 US claimed
EP-0553663-B1 Process for the preparation of thixotropic varnish binders based on alkyd resins BAYER AG (DE) 1995-05-03 EP claimed
EP-0553663-A1 Process for the preparation of thixotropic varnish binders based on alkyd resins BAYER AG (DE) 1993-08-04 EP claimed
EP-3420053-A1 ALKYLENE OXIDE- AND HYDROCARBYL-SUBSTITUTED POLYCARBOXYLIC ACID OF QUATERNIZED NITROGEN COMPOUNDS AS FRICTION-REDUCING ADDITIVE FOR FUELS BASF SE (DE) 2019-01-02 EP disclosed
WO-2017144376-A1 ALKYLENE OXIDE- AND HYDROCARBYL-SUBSTITUTED POLYCARBOXYLIC ACID OF QUATERNIZED NITROGEN COMPOUNDS AS FRICTION-REDUCING ADDITIVE FOR FUELS BASF SE (DE) 2017-08-31 WO disclosed
WO-2017144378-A1 HYDROPHOBIC POLYCARBOXYLIC ACIDS AS FRICTION-REDUCING ADDITIVE FOR FUELS BASF SE (DE) 2017-08-31 WO disclosed
WO-2017125358-A1 METHOD FOR THE HOMOGENEOUSLY CATALYZED PRODUCTION OF MONO-N-SUBSTITUTED PIPERAZINES BASF SE (DE) 2017-07-27 WO disclosed
US-20150272891-A1 DOSAGE FORMS COMPRISING APIXABAN AND MATRIX FORMER RATIOPHARM GMBH (DE) 2015-10-01 US disclosed
EP-2854759-A1 DOSAGE FORMS COMPRISING APIXABAN AND MATRIX FORMER ratiopharm GmbH (DE) 2015-04-08 EP disclosed
WO-2014023549-A1 METHOD FOR PRODUCING AMINES BY HOMOGENEOUSLY-CATALYZED ALCOHOL AMINATION IN THE PRESENCE OF A COMPLEX CATALYST, WHICH CONTAINS IRIDIUM AND AN AMINO ACID BASF SE (DE) 2014-02-13 WO disclosed
US-20140046054-A1 PROCESS FOR PREPARING AMINES BY HOMOGENEOUSLY CATALYZED ALCOHOL AMINATION IN THE PRESENCE OF A COMPLEX CATALYST COMPRISING IRIDIUM AND AN AMINO ACID BASF SE (DE) 2014-02-13 US disclosed
US-20010025020-A1 Compression process for multiphase tablets HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN(HENKEL KGAA) (DE) 2001-09-27 US disclosed
WO-2001044436-A1 METHOD FOR COMPACTING MULTI-PHASE DETERGENT AND CLEANSING-AGENT SHAPED BODIES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2001-06-21 WO disclosed
WO-2001042416-A1 PRESSING METHOD FOR MULTI-PHASE MOULDED BODIES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2001-06-14 WO disclosed
WO-2001027234-A1 CLEANING AGENT COMPONENTS WITH DUAL-CONTROLLED FRAGRANCE RELEASE HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2001-04-19 WO disclosed
WO-2001019948-A1 CLEAR RINSING AGENT HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2001-03-22 WO disclosed
WO-2001016283-A1 DETERGENT CONSTITUENT HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 2001-03-08 WO disclosed
US-5776934-A Use of 1,3,5-triazine-2,4,6-tris-alkylaminocarboxylic acid derivatives as biocidal agents in aqueous systems and cooling lubricants comprising these CG-CHEMIE GMBH (DE) 1998-07-07 US disclosed
EP-0553663-B1 Process for the preparation of thixotropic varnish binders based on alkyd resins BAYER AG (DE) 1995-05-03 EP disclosed
EP-0553663-A1 Process for the preparation of thixotropic varnish binders based on alkyd resins BAYER AG (DE) 1993-08-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150272891-A1 DOSAGE FORMS COMPRISING APIXABAN AND MATRIX FORMER VKORC1, VKORC1L1, PROC FFAR1 3394/4885FFAR4 2662/4885GPR84 3799/4885
US-20140046054-A1 PROCESS FOR PREPARING AMINES BY HOMOGENEOUSLY CATALYZED ALCOHOL AMINATION IN THE PRESENCE OF A COMPLEX CATALYST COMPRISING IRIDIUM AND AN AMINO ACID ADH1A, ADH5, ADH1C FFAR1 3610/4885FFAR4 3772/4885GPR84 1592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.